- Citro Soda batches were recalled after contamination risk and GMP failures were identified.
- Children’s products were removed from shelves as a precaution against potential harm.
- Wider national and regulatory systems are reinforcing strict compliance and patient safety.
In recent months, the South African Health Products Regulatory Authority (SAHPRA) has made critical regulatory decisions to ensure access to quality-assured medical products and to protect vulnerable communities from falsified or substandard health products.
These actions reflect a regulatory environment where compliance is enforced without exception and where patient safety remains the overriding priority.
No compromises on regulatory compliance
One example is the recall of specific batches of Citro Soda Regular products following the identification of a potential risk of foreign material contamination during an inspection at the Adcock Ingram facility in Clayville, Johannesburg, along with broader quality concerns, including non-compliance with Good Manufacturing Practices. This precautionary action underscores SAHPRA's commitment to protecting public health and ensuring that all health products meet required safety, quality, and efficacy standards.
Another example involves a medical product found to contain selenium zinc picolinate. SAHPRA requested that health professionals cease all distribution, sale, and dispensing of, and remove all selenium and zinc picolinate-containing products intended for children from stores, storage facilities, and shelves. This step reflects a precautionary approach, particularly where vulnerable groups may be exposed to potential risk.
Patient safety as a regulatory priority
Since its establishment in 2018, the South African Health Products Regulatory Authority has maintained patient safety as a central pillar of its mandate. Acting under the Medicines and Related Substances Act, 1965, SAHPRA is responsible for ensuring that medicines, medical devices, and other health products meet strict standards of safety, quality, and efficacy, while also facilitating timely access to these products. This balance between strict regulation and access remains fundamental to sustaining public confidence in the healthcare system.
The authority continues to take a proactive approach by establishing effective monitoring systems, enhancing regulatory oversight, and conducting inspections to ensure that all regulated entities comply with safety standards. This includes oversight across good manufacturing, clinical, laboratory, distribution, warehouse, and vigilance practices, ensuring that compliance is enforced across the entire value chain.
Strengthening systems through collaboration
SAHPRA has partnered with the United States Pharmacopeia to strengthen regulatory systems in South Africa and ensure the safety, quality, and efficacy of medicines, medical devices, and in vitro diagnostics. Through a Memorandum of Understanding, this collaboration supports SAHPRA's efforts to achieve the World Health Organization Maturity Level 4, the highest benchmark for regulatory performance.
This partnership enhances oversight of the local manufacturing sector, improves access to essential health products, and strengthens key regulatory functions, including risk-based inspections, post-market surveillance, and quality control systems. It also advances broader regulatory harmonisation efforts and supports regional cooperation to improve access to quality-assured health products across Africa.
A coordinated response to falsified medicines
The National Action Plan on substandard and falsified medical products stands as both a lifeline for the public and a blueprint for the continent. It responds directly to previously fragmented approaches by establishing a unified and coordinated system that strengthens detection, enforcement, and prevention. Through this framework, SAHPRA works to ensure that all communities, from rural health facilities to urban pharmacies, have access to safe and reliable medicines.
The urgency of this response is underscored by the scale of the problem. According to the World Health Organization, at least one in ten medical products in low and middle-income countries is substandard or falsified. These products contribute to treatment failure, serious health complications, and thousands of preventable deaths each year. Globally, falsified medicines are estimated to cost health systems more than 30 billion US dollars (USD) annually, while placing additional financial strain on households.
The National Action Plan also empowers communities to report suspicious products, enabling the public to play an active role in protecting their own health and strengthening early detection systems.
The role of media and public reporting
The media remains a critical partner in addressing the rise of substandard and falsified medical products. By leveraging its platforms, it plays a central role in amplifying warnings, increasing awareness, and strengthening public understanding of the risks associated with unsafe medicines. This expanded reach enhances consumer education and ensures that critical information is distributed effectively.
SAHPRA continues to prioritise accessibility by providing multiple channels for public engagement and reporting. Members of the public can direct general enquiries to enquiries@sahpra.org.za, while adverse side effects and safety concerns can be reported through the MedSafety app, which enables users to report unusual reactions and contribute to ongoing monitoring efforts.
By combining decisive enforcement, strengthened regulatory systems, and active public participation, SAHPRA is reinforcing a healthcare environment where there are no compromises on regulatory compliance and where patient safety remains the foundation of every decision.
Get your news on the go. Click here to follow the Conviction WhatsApp channel.
